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The term ’sepsis’ is often used synonymously with ’infection‘ or ’bacteremia‘. Additional definitions, e.g. ‘systemic 
inflammatory response syndrome’, have been proposed. These terms have been employed to  establish entry criteria 
for clinical trials of antibiotic therapy and adjunctive therapies. It may be appropriate to utilize these descriptions when 
initiating therapy of suspected bacterial infections, since culture confirmation is often not available for days after initial 
clinical presentation. Empiric antibiotic therapy is now the rule rather than the exception for febrile hospitalized patients. 
No antimicrobial agent is superior for all major clinical situations and thus history and physical examination are critical 
factors which guide the clinician. Guidelines have been derived for the initial empiric management of serious infection. 
While these were initially refined for the immunocompromized host, they may be considered generally applicable for 
the hospitalized patient with a suspected serious systemic bacterial infection. Currently, monotherapy with agents such 
as cefepime, ceftazidime, imipenem/cilastatin and meropenem has been sanctioned on the basis of their broad 
antimicrobial coverage and stability t o  clinically important p-lactamases (although there is considerable variation from 
one compound to  another). Perception of local epidemiologic patterns is a major factor in the selection of initial 
antibacterial therapy for hospital-acquired infection. 
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INTRODUCTION 
A major problem in the diagnosis and treatment of 
‘sepsis’ or ‘sepsis syndrome’ is knowing the infecting 
organism before culture confirmation [l]. As has 
been emphasized repeatedly, the ability to document 
bacterial infections in many of our hospitals is 
decreasing because empiric antimicrobial therapy has 
been initiated on an outpatient basis. Additionally, 
there may be serious limits on the diagnostic studies 
that clinicians can order or have readily available to 
them. Even when these limitations are overcome, there 
is difficulty in defining, prospectively, the type of 
infection that patients actually have. The traditional 
concept of ‘sepsis’ was ‘organisms in the blood’. The 
term was used interchangeably with ‘bacteremia’. 
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However, we now have newer concepts such as ‘sepsis 
syndrome’, systemic inflammatory response syndrome 
(SIRS), severe sepsis, and multiple organ dysfunction 
syndrome (MODS). The basis for the evolution of 
these concepts is the initial component of this review. 
ETIOLOGY AND DEFINITIONS 
In the 1960s, if an investigator wanted to summarize 
cases of Pseudomonas aeruginosa bacteremia for the 
literature, he or she could review the clinical records of 
patients with positive blood cultures as recorded in the 
hospital microbiology laboratory. Thus, there could 
be little doubt about the diagnosis of l? aeruginosa 
bacteremia. As we currently attempt to evaluate new 
antimicrobials or adjunctive therapies (e.g. therapies 
that do not kill bacteria but are aimed instead at 
neutralizing endotoxin or reversing the cytokine- 
induced tissue damage) on a prospective basis, we often 
do not know the cause of the underlying infectious 
disorder. Therefore, a new series of definitions are 
required in order to approach clinical conditions and 
stratify clinical conditions that can then be followed 
prospectively. 
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The diagnosis of ‘bacteremia’ is made only in 
retrospect, i.e. afier results of blood cultures are known. 
‘Septicemia’ is a term which has been used synony- 
mously with bacteremia. ‘Sepsis’ is a very loose term 
which is used interchangeably with ‘infection’, parti- 
cularly in the surgical literature. About 10 years ago, 
Bone and colleagues proposed the concept of ‘sepsis 
syndrome’, which referred to a clinical state charac- 
terized by evidence of infection with altered organ 
perfision and additional features such as hypo- 
oxygenation or lactic acidosis [3]. Most clinicians can 
understand what ‘septic shock‘ means. Fairly arbitrary 
blood pressure definitions have been advanced, and 
usually for the refractory septic shock definition we 
impose some time limit for reversibility (1 h has been 
used most often). However, except for untreated 
endocarditis or intravascular infection, most studies 
show that bacteremia is an intermittent phenomenon 
(i.e. not all blood cultures are positive) and this is one 
reason for the recommendation that multiple blood 
cultures should be obtained to document bacteremia. 
One of the most common, if not the most common, 
causes of negative blood cultures today is antecedent 
antimicrobial therapy that is given even before patients 
reach the hospital or the intensive care unit. 
A new set of clinical definitions which has built on 
the initial work of Bone et al is now widely accepted. 
These concepts are the result of the work of a consensus 
committee of the American College for Critical Care 
Medicine, with some input from infectious disease 
clinicians. These definitions are still considered to 
be rather general and non-specific (Table 1). How- 
ever, they have been conceived using a logical and 
evolutionary f?amework and they have been vahdated 
prospectively. The SIRS applies when two or more of 
the following features are present: pyrexia, tachycardia, 
tachypnea, and elevated or decreased white blood cell 
count. It must be conceded that an individual indulging 
in mild exercise may qualify for the diagnosis of SIRS, 
which is one of the reasons why this definition is 
considered too ‘loose’. ‘Sepsis’ is SIRS plus a culture- 
documented infection. ‘Severe sepsis’ refers to sepsis 
plus either organ dysfunction, hypoperfusion or hypo- 
tension (as defined by a systolic blood pressure of 
90 mmHg). The concept of hypoperfusion includes, 
but is not limited to, lactic acidosis, oliguria or 
alterations in mental status. For septic shock, the 
definition that most clinicians would accept is hypo- 
tension that persists for more than 1 h despite fluid 
resuscitation (e.g. infusion of 0.5-1.0 L of sahne or 
lactated Ringer’s solution). ‘MODS’ refers to the 
onset of organ failures such as acute renal failure, 
the adult respiratory distress syndrome (ARDS), and 
disseminated intravascular coagulation. 
Table 1 Definitions or terms used prospectively to 
describe infectious states 
Systemic inflammatory 
response syndrome (SIRS) the following: 
Presence of two or more of 
Sepsis 
Severe sepsis 
0 temperature >38”C or <36”C 
heart rate >90 beadmin 
0 respiratory rate >20 hreathdmin 
(or PaC02 <32  mmHg) 
0 white blood cell count 
> 12 000 mm3, <4000 mm3 or 
> 10% inmmature (band) forms 
SIRS plus documented infection 
Sepsis with organ dysfunction, 
hypoperfusion or hypotension 
Septic shock Sepsis-induced shock with 
hypotension despite adequate 
fluid resuscitation and organ 
dysfunction 
Adapted from Bone [ 3 ] .  
Criteria such as SIRS, sepsis and severe sepsis have 
been validated on a prospective basis by Wenzel and 
colleagues [5]. The validation has been in terms of 
prognosis and complications associated with a suspected 
infectious event. The criteria are likely to be applied 
increasingly, not only in studies of antimicrobial 
intervention, but in studies of adjunctive therapies. 
Even with SIRS there is a 2-6% risk of developing 
ARDS, but this percentage increases with each stepwise 
increase in clinical severity (Table 2). As shown in the 
table, the incidence of acute renal failure and the 
percentage of patients with positive blood cultures both 
increase in addition to the mortality when moving from 
SIRS to septic shock. Thus, this classification, however 
imperfect and subject to criticism, provides a useful 
framework for the evaluation of future studies of 
therapeutic intervention. 
It should be borne in mind that ‘sepsis’, particularly 
‘severe sepsis’ (in terms of these revised criteria), refers 
to disease states complicating an underlying disease. 
This is perhaps one reason why, at least in the evalua- 
tion of adjunctive therapies for sepsis syndrome, it has 
been dfficult to demonstrate that these interventions 
reduce mortality [6]. The overall failure to demonstrate 
better outcomes appears to be limited by the mortality 
that directly results &om the patient’s underlying disease 
~71. 
EPIDEMIOLOGIC TRENDS 
In terms of culturable entities from blood, major 
changes have been documented over the last two 
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Table 2 Morbidlty and mortality associated with the systemic inflammatory response syndrome (SIRS) and related clinical 
states 
Clinical state SIRS (%) Sepsis (%) Severe sepsis (96) Septic shock (%) 
ARDS 2-6 6 8 18 
DIC 8-1 9 16 18 38 
ARF 9-1 9 19 23 51 
Shock 11-27 20 28 100 
Positive blood cultures 17 25 69 
Mortality 7-1 7 16 20 46 
- 
ARDS, adult respiratory distress syndrome: ARE acute renal failure: DIC, disseminated intravascular coagulation 
Adapted from Rangel-Frausto et a1 [5] 
decades in Western Europe, North America and Asia. 
Serious systemic I? aeruginosa infections have actually 
declined in relation to other bacteremias, although 
mortality from this type of infection remains high [7]. 
Most recent clinical trials of new antibiotics show that 
Gram-positive cocci are now the most common 
bloodstream isolates. Overall, mortahty remains low in 
bloodstream infections caused by coagulase-negative 
staphylococci. There has clearly been an impressive 
increase in bloodstream infections caused by Candida 
species [7,8]. 
One of the largest multicenter groups for anti- 
microbial therapeutic trials, which focuses on neutro- 
penic cancer patients, is the European Organization for 
Research and Treatment of Cancer (EORTC). This 
group was organized several decades ago and it 
concentrated its initial efforts on developing empiric 
antimicrobial regimens for the treatment of febrile 
neutropenic patients. In the 1970s, Gram-negative 
bacilli were the major cause of bacteremia in this 
population. For example, 70% of the bloodstream 
Table 3 No antibiotic fits the bill completely 
isolates in the first EORTC trial were Gram-negative 
bacilli; only 29% were Gram-positive organisms [9]. 
However, by the late 1980s, the figures had almost 
reversed. A recent clinical trial performed by the 
EORTC showed roughly comparable benefit of 
meropenem monotherapy and a ‘classic’ regimen of 
ceftazidime plus amikacin [lo]. In this study, Gram- 
positive organisms accounted for 69% of single- 
organism bacteremia isolates, whilst Gram-negative 
organisms accounted for the remaining 31%. Never- 
theless, it is still widely accepted that systemic 
(bacteremic) Gram-negative bacillary infections cause 
greater mortality than those caused by Gram-positive 
cocci. This clearly may affect clinical decision-making 
in the choice of specific agents for empiric anti- 
microbial therapy. 
SELECTION OF ANTIMICROBIAL THERAPY 
How should clinicians choose antimicrobial agents for 
presumed sepsis? Today, one of the important criteria 
Pathogen Penicillins Cephalosporins Carbapenems 
Gram-positive 
Streptococcus pneumoniae + + + 
staphylococci + + + 
Coagulase-positive 
Coagulase-negative 
staphylococci OA OA OA 
MRSA OA OA OA 
Enterococci +” OA OA 
Gram-negative 
Coliforms + + + 
Enferobacter/Serratia spp. 2 2 + 
Pseudomonas spp. 2 ? + 
Stenotrophomonas maltophilia 2 2 
Anaerobes + 2 + 
+, active; ?, intermediately active; -, not active; OA, other agents preferred; MRSA, methicillin-resistant Staphylococcus aureus. 
”Must be combined with other antimicrobials. 
- 
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is clearly cost. The choice is also related to whether or 
not we even attempt to hospitahze patients. Major 
efforts are underway to try to treat patients on an 
outpatient basis or to rapidly speed their treatment in 
hospital and transfer them to a non-acute hospital 
treatment site. Approaches to treatment can, in fact, 
be divided into two major categories: one is agent- 
oriented, and the other is syndrome-oriented. The 
syndrome-oriented approach tries to identift. the most 
practical initial therapy according to the site of the 
infection and the degree of involvement without 
knowledge of the infecting pathogen. 
The problem with the organism-oriented approach 
is that no single antimicrobial agent comprehensively 
covers the spectrum of potential pathogens (Table 3). 
This should be evident to anyone who has spent any 
time in the microbiology laboratory or on the wards. 
Amongst Gram-positive cocci, methicillin-resistant 
staphylococci, enterococci and pneumococci demon- 
htr'iting high-level penicillin resistance are now the 
major challenges. In treating Gram-negative bacillary 
infections, the therapies that we have relied upon 
for the last decade are increasingly compromized by 
drug resistance. Cephalosporins, penicillinase-resistant 
penicillins and combinations containing p-lactamase 
inhibitors may not be effective in some cases of 
Enterobacter, Stenotrophomonas, and Pseudomonas infect- 
ions. 
The advantage of the syndromic approach is that it 
does not focus on the nature of the infecting bacterium 
at the initial stage of bedside evaluation. A clinical 
assessment can be carried out within 5-10 min in the 
emergency room or in the acute care clinic. A site that 
must be thoroughly examined, especially in children, is 
the central nervous system (CNS). Salvage of brain 
tissue function is related to the rapidity with which 
CNS-penetrating antimicrobial therapy can be delivered. 
A common rule in emergency rooms is that young 
patients presenting with fever (> 39OC) and headache 
or mental status changes should be given antimicrobial 
treatment within 45-60 min. Outside of the CNS, 
another area of concern is cellulitis. Rapidly progress- 
ing fi-hemolytic streptococcal disease (usually group A) 
has been associated with very high mortality. In cases 
of necrotizing fasciitis caused by group A streptococci 
(so called 'flesh-eating bacteria'), the clinical condition 
of the patient may deteriorate dramatically within 
hours. The clinical changes in patients with this form 
of necrotizing fasciitis have been compared with those 
of hlminant meningococcemia. 
The approach to pneumonia has triggered con- 
siderable controversy, which relates particularly to 
limitations in determining the etiology of lower 
respiratory disease [l l] .  We often do not know the 
cause of pneumonia but empiric therapy is usually 
called for. For intra-abdominal processes we have to 
consider both the Gram-negative organisms (which 
comprise the predominant aerobic component in the 
stool), the anaerobes (which predominate numerically) 
and the enterococci. In the case of genitourinary 
infection, the role of anatomic obstruction is extremely 
important. Most of the infecting pathogens in urinary 
tract infections are Gram-negative bacteria and this 
greatly simplifies the empiric therapy approach. 
CHOICE OF EMPlRlC THERAPY 
Other presentations during this symposium have 
addressed the subject of fi-lactamases and how they 
comprise an increasingly important mechanism of 
resistance against some of our most important anti- 
biotics. The proliferation of P-lactamase-related resist- 
ance has been generally linked to the overuse of 
antimicrobial agents. There is concern that after 50 
years we have lost the ability to treat a number of 
life-threatening infections. In choosing antimicrobial 
therapy, the seriousness of the clinical presentation, the 
status of the host and the development of infection 
in a nosocomial setting are factors that affect the 
aggressiveness of the clinical approach. Most clinicians 
are wdling to delay initiation of treatment, even in a 
febrile patient, if the physical examination indicates 
no obvious source of infection and there is no obvious 
immune deficit according to the history and the 
laboratory examination. 
Two societies whose interests include immuno- 
compromized patients have developed guidelines for 
the empiric use of antibiotics. In 1990 the Immuno- 
compromized Host Society (IHS) and the Infectious 
Diseases Society of America (IDSA) developed guide- 
lines for studying and prescribing antimicrobial therapy 
for febrile neutropenic patients [12,13]. The IDSA 
guidelines are currently under revision, but the newer 
version will not differ substantially fiom the guidelines 
that were published previously. 
Table 4 is a distillate of the IDSA recommendations 
which specifically addresses the initial management of 
the febrile neutropenic patient. These guidelines could 
probably also be applied to the empiric therapy of 
most critically ill, febrile patients. Clearly, it is not 
necessary to invoke these approaches for normal hosts 
with urosepsis, who can probably be treated with 
narrow-spectrum treatment directed against Gram- 
negative bacilli. These guidelines are appropriate for 
the seriously ill hospitalized patient in whom broad- 
spectrum therapy for sepsis or sepsis syndrome is being 
considered (irrespective of neutropenia) . 
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Table 4 Choice of antimicrobial regimens for use in seriously ill patients according to clinical factors 
Regimen 
Clinical factors 
Antipseudomonal 
p-lactam + 
aminogly coside 
Antipseudomonal 
penicillin + 
third-generation 
cephalosporin 
Single broad- 
spectrum 
p-lactam. 
Renal failure or 
VIII nerve damage 
Intra-abdominal focus 
- 
Use penicilhn 
+ 
+ 
+ 
+b 
rather than 
cephalosporin 
Vascular catheter- Add vancomycin Add vancomycin Add vancomycin 
Penicillin allergy (I@) Aztreonam' Aztreonam' Aztreonam' 
ANC < 100 m m 3  + d d 
ANC > 100 mm3 + + + 
+, regimen suitable; -, regimen unsuitable; ANC, absolute neutrophil count. 
a For example, ceftazidime, cefipime, imipenem/cilastatin, meropenem. 
bFor example, imipenem/cilastatin, meropenem, piperacillin/tazobactam. 
' Aztreonam lacks activity against Gram-positive bacteria and should always be used with either vancomycin or clindamycin. 
dAuthor's personal preference is for an aminoglycoside-containing regimen. 
associated infection 
The guidelines have identified at least three 
regimens which are considered to be reasonable alter- 
natives. Perhaps the most familiar is the 'classic' 
combination of an antipseudomonal p-lactam plus an 
aminoglycoside. The aminoglycoside component could 
be avoided if there is significant renal failure. The 
combination of an antipseudomonal penicillin and an 
antipseudomonal cephalosporin has been used in 
some hospital settings in the USA and the UK, and is 
often referred to as 'double p-lactam' treatment. This 
approach may appear redundant, in that similar targets 
are being affected. Double Ij-lactam regimens have not 
been shown to be superior to aminoglycoside-contain- 
ing regimens, but they appear to be less nephrotoxic. 
Single-agent p-lactam therapy is considered to be 
acceptable if one of the more potent agents is used, i.e. 
cefepime, ceftazidime, imipenem/cilastatin or mero- 
penem (amongst agents licensed in the USA and 
Europe). The revised IDSA guidelines will include an 
annotated bibliography of several hundred papers that 
have been published in this area. With a suspected 
anaerobic process (intra-abdominal disease), a penicillin 
rather than a cephalosporin should be preferred. The 
rationale for this is the slightly better activity of 
piperacillin or ticarcillin against anaerobes when 
combined with a p-lactamase inhibitor. The addition 
of vancomycin was felt to be indicated in the presence 
of vascular catheter-associated infection (not indwelllng 
urinary catheter). However, vancomycin is now being 
reserved for culture-documented susceptible Gram- 
positive coccal infections out of concern for selection 
of vancomycin-resistant enterococci (VRE) . 
For patients with penicillin allergy, the use of 
a third-generation cephalosporin has been recom- 
mended with some caution. Usually, a cephalosporin 
plus an aminoglycoside can replace a penicillin with an 
aminoglycoside in penicillin-allergic patients whose 
allergic response is skin rash (not urticaria). Whether an 
intravenous fluoroquinolone can replace an amino- 
glycoside in the initial regimen has been assessed to 
a limited degree. Parenteral fluoroquinolones may 
provide satisfactory anti-Gram-negative activity. If one 
were initiating use of an intravenous fluoroquinolone 
(and there is a limited number of published studies in 
critically ill patients), it would probably be prudent to 
combine that agent with either vancomycin, clinda- 
mycin, or a penicdhnase-stable antistaphylococcal 
penicillin. 
A continuing debate concerns the issue of mono- 
therapy versus combination therapy. Of the EORTC 
studies in profoundly neutropenic patients (with < 100 
neutrophils/mm3), a regimen of at least two agents 
aimed at Pseudomonas was preferred [14]. With the 
advent of the more potent p-lactam compounds 
(imipenem/cilastatin, meropenem and cefepime), there 
has been an attempt to compare monotherapy with 
combination therapy in febrile neutropenic patients, 
and meta-analyses have been performed for this purpose 
[15]. In fact, in the 21 studies that were reviewed, there 
was no difference in the overall outcome. However, the 
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authors were quick to acknowledge that all these 
studies lack adequate sample size in order to be able to 
detect the significant difference. In other words, these 
studies were ‘under-powered’, particularly in having 
adequate numbers of challenging bloodstream infect- 
ions caused by Pseudomonas, Serratia and Enterobacter 
species (where problems with new extended-spectrum 
p-lactamases have been particularly vexing). However, 
an aforementioned prospective randomized study per- 
formed by the EORTC compared meropenem with 
cefiazidime plus amikacin in 958 evaluable neutropenic 
cancer patients with profound and persistent neutro- 
penia. There was no statistically significant difference 
between the rates of clinical success achieved with two 
regimens, as assessed according to the stringent criteria 
of the IHS. 
Empiric antimicrobial selection should probably 
be based on factors other than perceived treatment 
superiority. This means that community and institution 
trends in antimicrobial resistance should provide the 
clinician with basic knowledge of which antimicrobial 
agents are likely to be effective. Another controversy is 
whether we should be ‘front-loading’ febrile patients 
with either teicoplanin or vancomycin. The emergence 
of the glycopeptide-resistant enterococci has probably 
more or less terminated this argument. Overall, the 
evidence for firont-loadmg with glycopeptides is modest. 
In most comparative studies there is evidence that 
vancomycin can be added following documentation of 
Gram-positive bloodstream infection without loss of 
benefit. 
CONCLUSION 
In the management of infectious disease, two lessons 
must be learned. First, drainage ofpus, surgical resection 
of necrotic tissue, the relief of obstruction and removal 
of foreign bodies are crucial and can have a far greater 
effect on outcome than choice of antimicrobial agent. 
Second, in septic immunocompromised patients, im- 
provement in host status (e.g. a rise in neutrophil count) 
is the principal determinant of outcome. 
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